<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14633253</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>11</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>09</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0042-9007</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>85</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Vox sanguinis</Title>
                <ISOAbbreviation>Vox Sang.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparison of various dimethylsulphoxide-containing solutions for cryopreservation of leucoreduced platelet concentrates.</ArticleTitle>
            <Pagination>
                <MedlinePgn>276-82</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Leucoreduced platelet concentrates (LR-PCs) can be stored at 20-24 degrees C for 5-7 days. When LR-PCs are cryopreserved they can be stored for several years. For cryopreservation to become applicable in blood-bank practice, an off-the-shelf cryoprotectant is needed that can be added to the LR-PC in a sterile manner. For this, we varied the composition of the cryopreservation medium and studied various parameters of cryopreserved LR-PCs for up to 24 h after thawing at room temperature.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">LR-PCs in plasma or Composol were concentrated and divided into 2 units. To each unit, an equal part of 10% dimethylsulfoxide (DMSO) in plasma, Composol with or without 5% albumin, or GPO (pasteurized plasma-protein solution) was added. Freezing occurred at 1 degrees C/min and LR-PCs were placed in the vapour phase of nitrogen. LR-PCs were thawed at 37 degrees C and stored at room temperature. LR-PCs were tested for morphology, platelet recovery, swirling effect, and activation antigens at various time-points thereafter.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">LR-PCs in 100%, 65% and 50% plasma supplemented with Composol showed good morphology scores (&gt;250), limited CD62P expression (&lt;35%), low CD63 expression (&lt;20%) and a swirling effect of about 2, at 24 h after thawing. At the same time-point, platelet recovery was &gt;80% under all conditions and CD42b expression varied between 70 and 85%. Results of LR-PCs in 15% plasma and Composol, with or without plasma substitutes, were not acceptable at 24 h after thawing, i.e. the morphology score was &lt;200 and the CD62P expression was &gt;40%.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A minimum of 50% plasma in the cryopreserved LR-PC is necessary to maintain an acceptable in vitro quality of platelets up to 24 h after thawing. Composol is a good candidate for using to prepare an off-the-shelf cryoprotectant.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dijkstra-Tiekstra</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Sanquin Blood Bank north west Region, Amsterdam, The Netherlands. m.dijkstra@sanquin.nl</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Korte</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pietersz</LastName>
                    <ForeName>R N I</ForeName>
                    <Initials>RN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reesink</LastName>
                    <ForeName>H W</ForeName>
                    <Initials>HW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Meer</LastName>
                    <ForeName>P F</ForeName>
                    <Initials>PF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verhoeven</LastName>
                    <ForeName>A J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>Evaluation Studies</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Vox Sang</MedlineTA>
            <NlmUniqueID>0413606</NlmUniqueID>
            <ISSNLinking>0042-9007</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Cryoprotective Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Serum Albumin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Solutions</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YOW8V9698H</RegistryNumber>
                <NameOfSubstance>Dimethyl Sulfoxide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Blood Platelets</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Blood Preservation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Cryopreservation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cryoprotective Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dimethyl Sulfoxide</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Filtration</DescriptorName>
                <QualifierName MajorTopicYN="N">instrumentation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukocyte Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Motion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Plasma</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Platelet Activation</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Serum Albumin</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Solutions</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>11</Month>
                <Day>25</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>11</Month>
                <Day>25</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14633253</ArticleId>
            <ArticleId IdType="pii">360</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
